Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs

International Journal of Mental Health Systems

Volumn 5, Issue , 2011, Pages

  Purgato, Marianna ^a,b   Barbui, Corrado ^a   Adams, Clive E ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIGESTAGEN; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE DECANOATE; GLUCOSE; HALOPERIDOL; MOOD STABILIZER; OPIATE AGONIST; OPIATE ANTAGONIST; PLACEBO; TUBERCULOSTATIC AGENT;

ARTICLE; COCHRANE LIBRARY; COMPARATIVE STUDY; DATA EXTRACTION; DRUG WITHDRAWAL; HUMAN; INTERVENTION STUDY; MEDICAL RECORD REVIEW; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 80053175808     PISSN: None     EISSN: 17524458     Source Type: Journal    
DOI: 10.1186/1752-4458-5-25     Document Type: Article

References (29)

1. The Cochrane Collaboration Working together to provide the best evidence for health care [Internet]. [cited 2011 May 16];Available from: http://www.cochrane.org/, The Cochrane Collaboration.
2. Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P, Moher M, Moher D. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998, 280:278-280. 10.1001/jama.280.3.278, 9676681.
3. Doyle J, Waters E, Yach D, McQueen D, De Francisco A, Stewart T, Reddy P, Gulmezoglu AM, Galea G, Portela A. Global priority setting for Cochrane systematic reviews of health promotion and public health research. J Epidemiol Community Health 2005, 59:193-197. 10.1136/jech.2003.019547, 1733031, 15709077.
4. WHO Evaluation of methods for the treatment of mental disorders. Report of a WHO Scientific Group on the Treatment of Psychiatric Disorders. World Health Organ Tech Rep Ser 1991, 812:1-75. WHO.
5. WHO mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings [Internet]. [cited 2011 Jan 6];Available from: http://www.who.int/mental_health/evidence/mhGAP_intervention_guide/en/index.html, WHO.
6. WHO Essential medicines [Internet]. [cited 2011 May 17];Available from: http://www.who.int/topics/essential_medicines/en/, WHO.
7. WHO WHO List of rejected drugs from the list of Essential Medicines [Internet]. [cited 2011 May 25];Available from: http://www.who.int/selection_medicines/committees/REJECTIONS.pdf, WHO.
8. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011, 64:383-94. 10.1016/j.jclinepi.2010.04.026, 21195583.
9. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, Thornicroft G, Hill S, Saxena S. Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders. PLoS Med 2010, 7:e1000322. 10.1371/journal.pmed.1000322, 2930877, 20824176.
10. Cochrane Schizophrenia Group Specialised Register: Cochrane Schizophrenia Group [Internet]. [cited 2011 May 17];Available from: http://szg.cochrane.org/cochrane-schizophrenia-group-specialised-register.
11. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998, 317:1181-1184. 28699, 9794850.
12. van Ommeren M, Barbui C, de Jong K, Dua T, Jones L, Perez-Sales P, Schilperoord M, Ventevogel P, Yasamy MT, Saxena S. If You Could Only Choose Five Psychotropic Medicines: Updating the Interagency Emergency Health Kit. PLoS Med 2011, 8:e1001030. 10.1371/journal.pmed.1001030, 3086873, 21559326.
13. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev 2005, 1:CD000307.
14. Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev 2008, 1:CD004278.
15. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007, 2:CD000284.
16. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database Syst Rev 2007, 1:CD006329.
17. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev 2009, 2:CD007778.
18. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 2010, 4:CD007445.
19. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006, 4:CD003082.
20. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst Rev 2002, 3:CD001951.
21. Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2009, 3:CD005146.
22. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006, 3:CD005581.
23. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002, 2:CD002305.
24. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007, 1:CD006391.
25. Gibson RC, Walcott G. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 2008, 4:CD006570.
26. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007, 3:CD003834.
27. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004, 1:CD004028.
28. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007, 3:CD001258.
29. Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst Rev 2005, 4:CD004719.1.